Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

July 27, 2016

Primary Completion Date

July 28, 2017

Study Completion Date

July 28, 2017

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

SOF/VEL

400/100 mg tablet administered orally once daily

Trial Locations (15)

Unknown

Hospital Clínic de Barcelona, Barcelona

Hospital Universitari Vall d'Hebron, Barcelona

Reina Sofía University Hospital, Córdoba

Hospital General Universitario Gregorio Maranon, Madrid

Hospital Ramón Y Cajal, Madrid

Hospital Universitario Virgen del Rocío, Seville

La Fe Hospital, Valencia

Hospital Clinico Zaragoza, Zaragoza

Universität Bern, Bern

University Hospital Zurich, Zurich

Cambridge University Hospitals NHS Foundation Trust, Cambridge

Royal Infirmary of Edinburgh, Edinburgh

St James University Hospital, Leeds

Kings College Hospital, London

Royal Free Hampstead NHS Trust, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY